Pharmaceutical The US Food and Drug Administration has approved under priority review Kerendia (finerenone), the first and only non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), German pharma major Bayer announced late Friday. 12 July 2021